首页> 美国卫生研究院文献>Journal of Korean Neurosurgical Society >The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis
【2h】

The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis

机译:P2Y12反应单位预测氯吡格雷浓度和改性的氯吡格雷血栓栓塞和出血并发症的疗效:荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The efficacy of P2Y12 reaction unit (PRU) of VerifyNow still remains as a controversial issue in neurointervention. So we investigated the usefulness of PRU of VerifyNow to predict the peri-procedural thromboembolic events (TE) and hemorrhagic events (HE). And we evaluated the safety of modified dual antiplatelet therapy (DAPT) or triple antiplatelet therapy (TAPT) for clopidogrel hyporesponders. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus on August 19 2018. Data was collected the 1) incidence of TE between clopidogrel responder and clopidogrel hypo-responder, 2) incidence of HE between clopidogrel hyper-responder and clopidogrel responder and hypo-responder, and 3) incidence of TE and HE between modified DAPT or TAPT and standard DAPT in clopidogrel hypo-responder. High cut-off value of PRU was defined as PRU >40% or <220. Fifteen studies were enrolled. Clopidogrel responder showed lower incidence of TE than hypo-responder (risk ratio [RR], 0.32; 95% confidence interval [CI], 0.17–0.61; p<0.001). With the high cut-off value of PRU, clopidogrel responder showed more lower incidence of TE than hypo-responder (RR, 0.11; 95% CI, 0.02–0.45; p=0.002). The incidence of periprocedural HE have higher on clopidogrel hyper-responder than clopidogrel responder and hypo-responder (RR, 4.26; 95% CI, 1.10–16.44; p=0.04; I2=66%). The incidence of periprocedural TE after changing regimen of DAPT for clopidogrel hypo-responder have a tendency to reduce, but there was no significant difference between modified DAPT or TAPT group and standard DAPT group (p>0.05). The incidence of periprocedural HE after changing regimen of DAPT for clopidogrel hypo-responder was no significant difference between modified DAPT or TAPT group and standard DAPT group (p>0.05). PRU is a useful tool as a predictor of peri-procedural TE or HE on neurointervention. PRU has a threshold effect of cut-off value to predict the peri-procedural TE. Modified DAPT or TAPT to prevent TE in clopidogrel hypo-responders could not reduce the incidence of TE. We should investigate the further research about modification of regiment on neurointervention.
机译:P2Y12反应单位(PRU)的效果仍然是神经诊断中的争议问题。因此,我们调查了PRU的有用性,以预测Peri-properationally血栓栓塞事件(TE)和出血事件(他)。我们评估了改良的双抗血小板治疗(DAPT)或三重抗血小板治疗(TAPT)的安全性,用于氯吡格雷次反应。我们搜索了Medline,Embase,Cochrane中央登记册,科学和Scopus于2018年8月19日。收集了氯吡格雷响应器和氯吡格雷克劳克响应的Te的发病率,2)他在Clopidogrel Hyper之间的发病率。 - 反应和氯吡格雷响应者和抑制剂和3)TE的发病率和他在氯吡格雷响应器中改进的DAPT或TAPT和标准DAPT之间的发病率。 PRU的高截止值定义为PRU> 40%或<220。十五项研究报名参加。氯吡格雷响应器显示TE的发病率降低而不是低响应器(风险比[RR],0.32; 95%置信区间[CI],0.17-0.61; P <0.001)。随着PRU的高截止值,Clopidogrel响应者显示Te的发病率比过呼吸响应器更低(RR,0.11; 95%CI,0.02-0.45; P = 0.002)。 Heriprocentuper的发生率在氯吡格雷的超响应者上具有比氯吡格雷响应者和低响应者(RR,4.26; 95%CI,1.10-16.44; P = 0.04; I2 = 66%)。改变氯吡格雷响应者DAPT方案后百分比的发病率倾向于减少,但改性DAPT或TAPT组和标准DAPT组无显着差异(P> 0.05)。改变氯吡格雷响应器的DAPT方案后纵横对象的发病率在改良的DAPT或TAPT组和标准DAPT组之间没有显着差异(P> 0.05)。 PRU是一个有用的工具,是Peri-Properation TE的预测因子,或者是神经诊断。 PRU具有截止值的阈值效果来预测Peri-Properation Te。修改的DAPT或TAPT以防止氯吡格雷克响应者的TE无法降低TE的发病率。我们应该探讨关于对神经治疗中军团修改的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号